Drug Combination Details
| General Information of the Combination (ID: C96418) | |||||
|---|---|---|---|---|---|
| Name | Cladribine NP Info | + | Entinostat Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | ||
| U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | |||
| MM1.R | CVCL_8794 | Plasma cell myeloma | Homo sapiens | |||
| Experimental
Result(s) |
Combinations of cladribine and entinostat exhibit potent activity to induce anti-proliferative/anti-survival effects on MM cells via induction of cell cycle G1 arrest, apoptosis, and DNA damage response. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle. 2018;17(8):985-996. | |||
